Martin Shkreli barred from drug industry and fined $64.6m by US court

Martin Shkreli barred from drug industry and fined $64.6m by US court

Martin Shkreli, the pharmaceutical entrepreneur vilified for astronomically hiking the price of a life-saving drug, has been barred for life from the pharmaceutical industry and fined $64.6m by a US court.

The Friday ruling came after the Federal Trade Commission (FTC) and seven states brought a case against Shkreli, nicknamed the “Pharma Bro” for his sometimes outrageous behavior.

Shkreli was chief executive of Turing Pharmaceuticals, a company that in 2015 hiked the price of Daraprim, a drug used to treat Aids, malaria and cancer, by more than 5,000%.